In a move that marks the conclusion of one of the most volatile chapters in the history of the U.S. Food and Drug Administration, Marty Makary has resigned as the agency’s commissioner. His departure, confirmed by President Trump during a briefing with reporters on Tuesday, brings an abrupt end to a tenure characterized by bold, disruptive efforts to overhaul the nation’s primary health regulator—efforts that ultimately collided with the realities of bureaucratic management and political pressure.
President Trump, while acknowledging the resignation, maintained a conciliatory tone regarding his former appointee. "Marty’s a great guy, he’s a friend of mine, and he’s a wonderful man," Trump stated. "He was having some difficulty, but he’s going to go on and he’s going to do well. Everybody wants that job."
The administration has moved quickly to fill the power vacuum, appointing Kyle Diamantis, the former deputy commissioner for food, to serve as acting commissioner. As the search for a permanent successor begins, the agency is left to grapple with the legacy of a leader who sought to tear down "groupthink" but leaves behind an institution struggling with severe internal turnover and waning industry confidence.
A Chronology of a Controversial Command
The trajectory of Marty Makary’s time at the FDA was defined by a rapid transition from a highly anticipated academic reformer to a polarizing administrator.
- November 2024: President Trump nominates Makary, a prolific surgeon, researcher, and author, to lead the FDA. Seen as a traditional, albeit vocal, academic, his nomination is met with cautious optimism by the pharmaceutical sector.
- March 2025: Makary sails through his Congressional confirmation hearing with little resistance, signaling a mandate to modernize the agency.
- May 2025: Makary appoints controversial critic Vinay Prasad to head the Office of Vaccines and Gene Therapies (CBER), signaling a desire to disrupt the status quo.
- November 2025: George Tidmarsh, the head of the Center for Drug Evaluation and Research (CDER), resigns amid a conduct investigation, marking the beginning of a period of executive instability.
- January 2026: Reports emerge of internal tensions as Makary pushes to allow single-trial approvals for new drugs, drawing skepticism from career regulators.
- April 2026: Vinay Prasad resigns for the second time, highlighting the revolving door nature of the agency’s leadership under Makary.
- May 2026: Makary resigns as FDA Commissioner.
The Vision: Disrupting "Groupthink"
When Makary took the helm, he arrived with a clear manifesto. An outspoken critic of what he termed scientific "groupthink"—a phenomenon he explored extensively in his book Blind Spots—Makary campaigned on the idea that the FDA had become overly risk-averse, stifling innovation through rigid, antiquated processes.
He wasted little time in translating his philosophy into policy. His primary objective was to accelerate the speed of drug development, a goal he pursued through a series of radical structural changes:
- The Single-Trial Paradigm: Perhaps his most controversial policy was the push to require only one pivotal clinical trial for certain drug approvals, moving away from the industry standard of two.
- The "N-of-1" Framework: Makary championed a new approval pathway for ultra-rare diseases, utilizing AI-driven data and individualized trial methodologies to bring therapies to market faster.
- Voucher Programs: He introduced a new national priority review voucher program intended to incentivize investment in high-need medical areas.
- AI Integration: Makary aggressively pushed for the integration of artificial intelligence in the review process, hoping to clear backlogs that have plagued the agency for years.
The Reality: Operational Instability and Regulatory Confusion
While Makary’s intentions were rooted in accelerating patient access to life-saving medicines, the implementation of these policies was marred by systemic instability. The agency’s internal culture, already reeling from mass layoffs and restructuring, became increasingly fractured under his leadership.
The Turnover Crisis
The most glaring issue during the Makary era was the unprecedented turnover at the executive level. The departure of high-profile figures like George Tidmarsh and the erratic employment status of Vinay Prasad created an atmosphere of uncertainty. When Makary attempted to appoint long-time oncology lead Richard Pazdur to head CDER, the move backfired; Pazdur, citing deep-seated disagreements with Makary’s "accelerate at any cost" philosophy, briefly resigned before the role was eventually handed to Tracy Beth Hoeg.
Industry Frustration
The biotech and pharmaceutical industries, which initially hoped for a more flexible regulator, found themselves in a state of paralysis. Analysts at firms like Stifel noted that the agency’s ability to provide consistent guidance had hit a decade-long low.
The most prominent example of this confusion occurred during the review process for a gene therapy for Huntington’s disease. After seemingly signaling approval, the agency made a sudden about-face, leaving the manufacturer and investors blindsided. Such unpredictability is the antithesis of the regulatory certainty that the industry requires to secure funding and plan clinical timelines.
Official Responses and Political Pressures
The silence from the Department of Health and Human Services (HHS) following the resignation speaks volumes about the tense relationship between the agency and the current administration. However, the external pressures on Makary were no secret.
Reports from the Wall Street Journal and other outlets suggest that the FDA was being used as a political lever. Makary found himself caught between the competing interests of the administration’s base and the scientific community. Anti-abortion advocacy groups had reportedly expressed deep frustration with his perceived lethargy regarding the safety review of mifepristone. Simultaneously, President Trump had personally pressured the commissioner to bypass traditional review timelines to fast-track the approval of flavored vaping products—a direct challenge to the FDA’s public health mandate.
These dual pressures forced Makary into a corner: he was simultaneously accused of moving too fast by career scientists and too slowly by his political superiors.
Implications: The Road Ahead for the FDA
The resignation of Marty Makary leaves the FDA at a critical juncture. The agency is currently attempting to emerge from a multiyear downswing in the biotechnology sector, and stability is paramount for the "ship to be righted."
John Crowley, head of the Biotechnology Innovation Organization (BIO), summarized the sentiment of the industry: "We need organizational strength and stability at the agency. It is time to right the ship."
What comes next?
The appointment of Kyle Diamantis as acting commissioner is likely a stop-gap measure intended to calm the waters while the administration identifies a permanent replacement. The next commissioner will face three immediate challenges:
- Restoring Institutional Morale: The mass layoffs and the rapid turnover of leadership have left the agency’s civil servants demoralized. Rebuilding the scientific core of the FDA will be a multi-year project.
- Harmonizing Innovation with Safety: The next leader must find a way to maintain the speed of drug development without sacrificing the rigorous data requirements that protect public safety. The "single-trial" debate remains unresolved and will likely be the first major policy test for the new administration.
- Navigating Political Independence: Perhaps the most difficult task will be shielding the FDA from the political interference that characterized the final months of the Makary era. If the FDA is to remain the gold standard for global health regulation, it must be perceived as independent of the whims of the White House.
As the industry looks toward the future, the tenure of Marty Makary serves as a cautionary tale: in the high-stakes world of public health, ideological zeal is no substitute for steady, predictable, and deeply institutionalized governance. The FDA now enters a period of reconstruction, tasked with finding a middle path between the radical reform of the past year and the rigid bureaucracy that preceded it.
About the Author
